RLAY: Bull Flag detected on 16 Jul 2026

RLAY is forming a bull flag pattern with solid technical quality metrics. Structure scores 15.0/15, volume 12.0/12, and breakout strength at 10.1/13, yielding an overall score of 77.1/98 with 74.17% win probability. The stock trades at $19.51, having rallied 31.74% over one month and 32.27% over three months. Support sits at $18.33, resistance at $20.79, with a conservative target of $20.15. RSI at 60.97 shows moderate momentum without overbought extremes. Current volume of 1.54M shares represents only 33% of the 20-day average, signaling low participation—a volume concern that weakens breakout conviction despite the bullish price structure.

RLAY reported Q1 2026 results on May 5, 2026, achieving FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer with 11.1-month median PFS in CDK4/6-experienced patients. The company held $642.1M in cash and investments at March 31 with $73.3M net loss and $3.0M revenue in Q1. Management expects initial zovegalisib data in vascular anomalies at ISSVA and is preparing a Phase 3 frontline study in endocrine-sensitive metastatic breast cancer patients. RLAY completed a public offering in May 2026 at $12.00/share generating ~$275M in proceeds. The strong clinical progression, regulatory tailwind, and adequate cash runway funded by recent capital raise explain the sharp 32% three-month gain and current pattern formation as market sentiment shifts from funding anxiety to clinical validation optimism.

A successful bull flag breakout would see RLAY clear resistance at $20.79 with volume acceleration above the 4.6M-share 20-day average—currently a critical gap at only 0.33x relative volume. The measured move target of $20.15 is modest, suggesting initial phase of breakout to that level, with subsequent targets dependent on larger macroeconomic and clinical catalyst confirmation. Invalidation occurs below support at $18.33, which represents roughly 6% downside from current levels. The 74.17% win probability reflects historical bull flag success rates, though the below-average volume participation introduces execution risk that could suppress breakout velocity even if directional bias holds.

Despite positive pipeline fundamentals, most of RLAY's prior earnings days saw negative 24-hour reactions, creating a pattern of news-sensitive volatility. The company remains clinical-stage with no approved products, carrying binary trial risk through 2027-2028. Beta of 1.0 masks individual stock event risk around Phase 3 ReDiscover-2 data readouts and vascular anomaly trial updates. Volume drought (33% of average) may indicate insufficient institutional conviction to sustain a breakout; low participation could trap retail buyers if negative data surprises occur. The recent $275M offering at $12.00 provides near-term float overhang as underwriter lock-up windows expire in coming months.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.